Company intelligence / Profile preview

454 Life Sciences

Branford, Connecticut, United States

Ownership: Private
Employees: ~167
Development stage: Other

Overview

454 Life Sciences pioneered high-throughput DNA sequencing with its sequencing-by-synthesis platform, commercialized as the first 'next-generation' sequencing system (GS20, GS FLX). Achieved milestones such as the sequencing of the first Neanderthal genome and James Watson's genome, but no therapeutic clinical trials were conducted as the company was a technology platform provider, not a therapeutics developer.[2][3][1]

Industry: Molecular Diagnostics

Partnerships

Roche Diagnostics (exclusive worldwide distributor and later acquirer)CuraGen (majority owner until 2007)

Beyond the preview

Go deeper on 454 Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 454 Life Sciences.

Explore the full profile